Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5938227 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL22784207 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL43652 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL29560774 | 1.00 | NR1H2 (0.50) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL29965040 | 0.93 | LIPE (0.45) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL14239659 | 0.91 | NR1H2 (0.48) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL1692080 | 0.91 | NR1H2 (0.48) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL5940329 | 0.86 | NR1H2 (0.54) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL5938643 | 0.86 | NR1H2 (0.54) | NR1H2LIPEDDB1CRBNUSP30 | |
| SCHEMBL14239632 | 0.84 | NR1H2 (0.52) | NR1H2LIPEDDB1CRBNUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210024525-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-8796470-B2 | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2012169934-A1 | NOVEL KINASE INHIBITORS | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "АСИНЭКС МЕДХИМ" (RU) | 2012-12-13 | — | — | WO | disclosed |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| WO-2011149993-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024525-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | NR1H2 417/4885LIPE 1956/4885DDB1 3049/4885 |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | EPOR, ACAD9, CBR1 | NR1H2 997/4885LIPE 4815/4885DDB1 4438/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | NR1H2 417/4885LIPE 1956/4885DDB1 3049/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | NR1H2 417/4885LIPE 1956/4885DDB1 3049/4885 |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ORAI1, CACNA1E, RYR1 | NR1H2 1912/4885LIPE 3955/4885DDB1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.